by Lee Jungyun
Published 22 Jun.2023 11:16(KST)
Panagen surged on news of being acquired by HLB.
As of 11:14 AM on the 22nd, Panagen was trading at 5,790 KRW, hitting the price limit increase of 29.97%.
Panagen announced that it decided to conduct a third-party allotment paid-in capital increase targeting HLB, an anticancer drug development company, among others, to raise 30 billion KRW in operating funds. HLB's strategy is to expand its business areas not only in anticancer drugs but also in diagnostics through the acquisition of Panagen.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.